Effects of Night-Time Use of Rotigotine on Nocturnal Symptoms in Parkinson’s Disease

Table 1

Baseline demographic and clinical characteristics.

Characteristic	Safety population ()
Age, years	71.5 ± 8.6
Gender
Male, (%)	44 (54.3)
Female, (%)	37 (45.7)
Time since first diagnosis, years	5.6 ± 5.2
Hoehn and Yahr stage, (%)
I	17 (21)
II	33 (40.7)
III	27 (33.3)
IV	4 (4.9)
PDSS-2 total score	23.3 ± 8.8
PDQ-8 score	24.2 ± 19.2
VAS-pain score	3.2 ± 2.6
CGI-S score	3.7 ± 0.6
Concomitant dopaminergic medication, (%)	81 (100)
Levodopa preparations	70 (86.4)
Dopamine agonists	32 (39.5)
MAO-B inhibitors	31 (38.3)
Entacapone	2 (2.5)
Major complaints of patients who received nocturnal rotigotine, (%)
Difficulty maintaining sleep	71 (87.7)
Nocturia	56 (69.1)
Difficulty falling asleep	46 (56.8)
Nocturnal/early morning akinesia	42 (51.9)
Restless legs	42 (51.9)
Vivid dreams	41 (50.6)
Pain in arms and legs	31 (38.3)

Unless otherwise specified, data are mean ± standard deviation.
CGI-S, Clinical Global Impression of Severity; MAO-B, monoamine oxidase B; PDQ-8, short-form Parkinson’s Disease Questionnaire; PDSS, Parkinson’s Disease Sleep Scale; VAS, visual analogue scale.